ALT
Altimmune, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C+
Company Profile
CEO
Jerome Benedict Durso
IPO Date
2017-05-26
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Altimmune, Inc.
CEO
Jerome Benedict Durso
IPO Date
2017-05-26
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 48,800 |
| $2.82 |
| 1 May 2026 | Jorkasky Diane | director | A-Award | Acquired | 48,800 | $2.82 |
| 1 May 2026 | Schafer Klaus | director | A-Award | Acquired | 48,800 | $2.82 |
| 1 May 2026 | Pisano Wayne | director | A-Award | Acquired | 48,800 | $2.82 |
| 1 May 2026 | Hodges Philip | director | A-Award | Acquired | 48,800 | $2.82 |
| 1 May 2026 | GILL JOHN | director | A-Award | Acquired | 48,800 | $2.82 |
| 1 May 2026 | SAYARE MITCHEL | director | A-Award | Acquired | 48,800 | $2.82 |
| 6 Apr 2026 | GILL JOHN | director | P-Purchase | Acquired | 9,200 | $3.41 |
| 1 Apr 2026 | WEAVER GREGORY L | Chief Financial Officer | P-Purchase | Acquired | 10,000 | $3.15 |